A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
Identifieur interne : 002594 ( Main/Exploration ); précédent : 002593; suivant : 002595A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
Auteurs : Lanying Du [États-Unis] ; Guangyu Zhao ; Chris C S. Chan ; Lin Li ; Yuxian He ; Yusen Zhou ; Bo-Jian Zheng ; Shibo JiangSource :
- Viral immunology [ 1557-8976 ] ; 2010.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Anticorps neutralisants (immunologie), Anticorps neutralisants (sang), Cellules CHO, Cricetinae, Cricetulus, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (), Glycoprotéines membranaires (immunologie), Injections sous-cutanées, Protéines de l'enveloppe virale (), Protéines de l'enveloppe virale (immunologie), Récepteurs viraux (métabolisme), Souris, Souris de lignée BALB C, Spécificité des anticorps, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins synthétiques.
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins synthétiques, Virus du SRAS.
- métabolisme : Récepteurs viraux.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Animaux, Cellules CHO, Cricetinae, Cricetulus, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Injections sous-cutanées, Protéines de l'enveloppe virale, Souris, Souris de lignée BALB C, Spécificité des anticorps, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Neutralizing (immunology), Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, CHO Cells, Cricetinae, Cricetulus, Female, Injections, Subcutaneous, Membrane Glycoproteins (chemistry), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Protein Structure, Tertiary, Receptors, Virus (metabolism), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (chemistry), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, Synthetic, Viral Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , chemistry : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Membrane Glycoproteins, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Receptors, Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, CHO Cells, Cricetinae, Cricetulus, Female, Injections, Subcutaneous, Mice, Mice, Inbred BALB C, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus.
Abstract
Development of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine.
DOI: 10.1089/vim.2009.0090
PubMed: 20374001
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001720
- to stream PubMed, to step Curation: 001720
- to stream PubMed, to step Checkpoint: 001725
- to stream Ncbi, to step Merge: 002110
- to stream Ncbi, to step Curation: 002110
- to stream Ncbi, to step Checkpoint: 002110
- to stream Main, to step Merge: 002633
- to stream Main, to step Curation: 002594
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="1"><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10065</wicri:regionArea><wicri:noRegion>New York 10065</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Chan, Chris C S" sort="Chan, Chris C S" uniqKey="Chan C" first="Chris C S" last="Chan">Chris C S. Chan</name></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author><author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20374001</idno><idno type="pmid">20374001</idno><idno type="doi">10.1089/vim.2009.0090</idno><idno type="wicri:Area/PubMed/Corpus">001720</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001720</idno><idno type="wicri:Area/PubMed/Curation">001720</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001720</idno><idno type="wicri:Area/PubMed/Checkpoint">001725</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001725</idno><idno type="wicri:Area/Ncbi/Merge">002110</idno><idno type="wicri:Area/Ncbi/Curation">002110</idno><idno type="wicri:Area/Ncbi/Checkpoint">002110</idno><idno type="wicri:Area/Main/Merge">002633</idno><idno type="wicri:Area/Main/Curation">002594</idno><idno type="wicri:Area/Main/Exploration">002594</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="1"><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10065</wicri:regionArea><wicri:noRegion>New York 10065</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name></author><author><name sortKey="Chan, Chris C S" sort="Chan, Chris C S" uniqKey="Chan C" first="Chris C S" last="Chan">Chris C S. Chan</name></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author><author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></analytic><series><title level="j">Viral immunology</title><idno type="eISSN">1557-8976</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Specificity</term><term>CHO Cells</term><term>Cricetinae</term><term>Cricetulus</term><term>Female</term><term>Injections, Subcutaneous</term><term>Membrane Glycoproteins (chemistry)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Protein Structure, Tertiary</term><term>Receptors, Virus (metabolism)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (chemistry)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (immunologie)</term><term>Anticorps neutralisants (sang)</term><term>Cellules CHO</term><term>Cricetinae</term><term>Cricetulus</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires ()</term><term>Glycoprotéines membranaires (immunologie)</term><term>Injections sous-cutanées</term><term>Protéines de l'enveloppe virale ()</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Récepteurs viraux (métabolisme)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Membrane Glycoproteins</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Specificity</term><term>CHO Cells</term><term>Cricetinae</term><term>Cricetulus</term><term>Female</term><term>Injections, Subcutaneous</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Protein Structure, Tertiary</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules CHO</term><term>Cricetinae</term><term>Cricetulus</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires</term><term>Injections sous-cutanées</term><term>Protéines de l'enveloppe virale</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Development of vaccines is essential for the prevention of future recurrences of severe acute respiratory syndrome (SARS), caused by the SARS coronavirus (SARS-CoV). The spike (S) protein, especially receptor-binding domain (RBD) of SARS-CoV, plays important roles in the prevention of SARS infection, and is thus an important component in SARS vaccine development. In this study, we expressed a 219-mer (residues 318-536) RBD protein in Chinese hamster ovary (CHO)-K1 cells (RBD219-CHO), and tested its immune responses and protective immunity in a mouse model. The results showed that this recombinant protein was correctly folded, being able to maintain intact conformation and authentic antigenicity. It could induce strong humoral and cellular immune responses and high titers of neutralizing antibodies in the vaccinated mice. RBD219-CHO protein elicited potent protective immunity that protected all vaccinated mice from SARS-CoV challenge. These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Chan, Chris C S" sort="Chan, Chris C S" uniqKey="Chan C" first="Chris C S" last="Chan">Chris C S. Chan</name><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002594 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002594 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20374001
|texte= A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20374001" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |